SLC38A2 and neoplasm: Furthermore, the heterogeneity of the immune microenvironment further limits therapeutic efficacy: competitive uptake of glutamine by tumor cells via SLC38A2 significantly impairs the antigen-presenting capacity of dendritic cells (33), while MDSCs and TAMs exhibit enhanced immunosuppressive activity under glutamine-deficient conditions (79).